Brandon Essink
Velocity Clinical Research (United States)(US)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Viral gastroenteritis research and epidemiology, Respiratory viral infections research, Animal Virus Infections Studies, COVID-19 Clinical Research Studies
Most-Cited Works
- → Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase(2021)653 cited
- → A Bivalent Omicron-Containing Booster Vaccine against Covid-19(2022)641 cited
- → Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years(2021)158 cited
- → Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial(2022)143 cited
- → Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons(2024)142 cited
- → The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials(2023)136 cited
- → Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study(2021)123 cited
- → Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study(2017)120 cited
- → Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial(2022)113 cited
- → Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant(2013)85 cited